Department of Urology Surgery, Binhai County Hospital of TCM, Yancheng, Jiangsu 224500, P.R. China.
Department of Urology Surgery, Heqiao Hospital, Heqiao, Yixing, Jiangsu 214200, P.R. China.
Mol Med Rep. 2022 Jul;26(1). doi: 10.3892/mmr.2022.12747. Epub 2022 May 26.
A growing number of dysregulated long non‑coding (lnc)RNAs have been verified to serve an essential role in human prostate cancer. However, the underlying mechanisms of lncRNA MNX1 Antisense RNA 1 (MNX1‑AS1) in prostate cancer has not been explored. Therefore, the present study aimed to explore the function of MNX1‑AS1 in prostate cancer tumorigenesis and investigate the in‑depth mechanism. The expression of MNX1‑AS1, microRNA (miR)‑2113 and murine double min 2 (MDM2) in prostate cancer tissues and corresponding normal tissues were assessed by reverse transcription‑quantitative PCR. The protein expression levels of MDM2 were detected by western blotting. LNCaP and PC‑3 cells were transfected with short hairpin (sh)‑MNX1‑AS1, miR‑2113 mimics, miR‑2113 inhibitor and pCDH‑MDM2 vector using Lipofectamine 3000. Cell proliferation, migration and invasion abilities were assessed by CCK‑8 assay, colony formation and Transwell assay, respectively. Dual luciferase reporter assay was carried out to confirm the putative targets of MNX1‑AS1 and miR‑2113. Tumor formation experiment in nude mice was applied to evaluate the tumor growth effect of MNX1‑AS1 . The expression of MNX1‑AS1 was significantly upregulated in the prostate cancer tissues and cell lines. MNX1‑AS1 knockdown suppressed the abilities of cell viability and migration and invasion and inhibited tumor growth . Additionally, luciferase reporter assay revealed that MNX1‑AS1 could target miR‑2113 and negatively interacted with miR‑2113 in prostate cancer cells. miR‑2113 directly targeted to MDM2 and negatively modulated the expression of MDM2. Rescue assays suggested that the viability, migration and invasion of impaired cells triggered by transfection with sh‑MNX1‑AS1 alone could be recovered by co‑transfection with sh‑MNX1‑AS1 + miR‑2113 inhibitor or sh‑MNX1‑AS1 + pCDH‑ MDM2 vector. The present study demonstrated that MNX1‑AS1 promoted prostate cancer progression through regulating miR‑2113/ MDM2 axis.
越来越多失调的长非编码 RNA(lncRNA)已被证实在人类前列腺癌中发挥重要作用。然而,lncRNA MNX1 反义 RNA 1(MNX1-AS1)在前列腺癌中的潜在机制尚未被探索。因此,本研究旨在探讨 MNX1-AS1 在前列腺癌肿瘤发生中的作用,并深入研究其机制。通过逆转录定量 PCR 检测前列腺癌组织及相应正常组织中 MNX1-AS1、微小 RNA(miR)-2113 和鼠双微体 2(MDM2)的表达。采用 Western blot 检测 MDM2 蛋白表达水平。采用 Lipofectamine 3000 将短发夹 RNA(sh)-MNX1-AS1、miR-2113 模拟物、miR-2113 抑制剂和 pCDH-MDM2 载体转染至 LNCaP 和 PC-3 细胞。通过 CCK-8 测定、集落形成和 Transwell 分析分别评估细胞增殖、迁移和侵袭能力。采用双荧光素酶报告基因检测验证 MNX1-AS1 和 miR-2113 的潜在靶标。裸鼠肿瘤形成实验用于评估 MNX1-AS1 的肿瘤生长效应。前列腺癌组织和细胞系中 MNX1-AS1 的表达明显上调。MNX1-AS1 敲低抑制细胞活力和迁移侵袭能力,并抑制肿瘤生长。此外,荧光素酶报告基因检测显示,MNX1-AS1 可靶向 miR-2113,并在前列腺癌细胞中与 miR-2113 负相互作用。miR-2113 直接靶向 MDM2 并负调控 MDM2 的表达。挽救实验表明,单独转染 sh-MNX1-AS1 引起的细胞活力、迁移和侵袭受损可通过共转染 sh-MNX1-AS1+miR-2113 抑制剂或 sh-MNX1-AS1+pCDH-MDM2 载体恢复。本研究表明,MNX1-AS1 通过调节 miR-2113/MDM2 轴促进前列腺癌进展。